Cleerly
See Cleerly. Act early.
IvaraX Analysis
Cleerly provides an AI-powered cardiac imaging analysis platform that quantifies coronary artery disease through non-invasive CCTA scans. The company's clinically validated technology helps healthcare providers personalize heart attack prevention strategies by delivering detailed insights into plaque characteristics and stenosis severity.
Key Strengths
- +Strong clinical validation through prospective trials showing superior diagnostic accuracy compared to traditional testing methods
- +Comprehensive analysis capabilities covering plaque characterization, stenosis evaluation, and ischemia detection
- +Established insurance coverage and clear billing guidelines for healthcare providers
- +Non-invasive approach that can reduce patient burden and potentially eliminate need for additional testing
- +Focus on actionable insights that support personalized treatment decisions
Ideal For
- →Healthcare systems and cardiology practices seeking advanced CAD diagnostic capabilities
- →Health insurers and payors looking to improve cardiac care outcomes and reduce unnecessary invasive procedures
- →Patients at risk for coronary artery disease who want comprehensive, non-invasive heart health assessment
- →Medical facilities with CCTA imaging capabilities seeking AI-enhanced analysis tools
Things to Consider
- !Requires CCTA imaging infrastructure or referral relationships with imaging centers
- !Healthcare providers should verify specific insurance coverage in their region as commercial coverage is expanding
- !Integration into existing clinical workflows may require staff training and process adjustments
About Cleerly
Cleerly is a healthcare technology company that has developed an AI-driven platform specifically designed to quantify and assess coronary artery disease (CAD). Their innovative solution analyzes coronary computed tomography angiography (CCTA) images to provide comprehensive insights into heart health, measuring plaque volume, composition, length, and location while evaluating stenosis severity. This approach enables clinicians to make more informed decisions about heart attack prevention strategies. The company offers multiple products including Cleerly Plaque Analysis, Cleerly ISCHEMIA, and Cleerly COMPARE, all delivered through a web-based platform. Their technology has been validated through clinical trials including the CREDENCE and PACIFIC studies, which demonstrated high diagnostic accuracy compared to other testing methods. Cleerly's platform serves healthcare providers, payors, and ultimately patients by potentially reducing the need for additional invasive testing while enhancing diagnostic confidence. Cleerly operates at the intersection of artificial intelligence and cardiovascular medicine, focusing on the personalized analysis and treatment of heart disease. With coronary artery disease accounting for over 900,000 fatalities annually, the company aims to help physicians assess patient risk more accurately through non-invasive means, enabling earlier intervention and more targeted treatment approaches.
Why Choose Cleerly
- AI-enabled platform with clinically validated accuracy demonstrated in prospective, multicenter trials (CREDENCE and PACIFIC)
- Comprehensive plaque analysis measuring volume, composition, length, and location for detailed disease characterization
- Non-invasive approach that may reduce the need for additional testing while enhancing diagnostic confidence
- Web-based solution with established billing guidelines and commercial insurance coverage
- Prognostic capability for predicting future major adverse cardiac events (MACE)
Services
AI-enabled CCTA analysisCleerly Plaque AnalysisCleerly ISCHEMIACleerly COMPARECoronary artery disease assessment
Technologies
AIMachine LearningWeb-based platform
Tech Stack(detected from website)
AI/Machine LearningWeb-based platformCloud-based deliveryMedical imaging analysis
Industries Served
Categories
Company Info
- Headquarters
- US
